Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Jamila Louahed

Jamila Louahed, Rixensart BE

Patent application number	Description	Published
20100008980	Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer - A combination therapy comprising an immunotherapy based on a tumour antigen or an immunological derivative thereof, and at least one other treatment for cancer such as chemotherapy, radiotherapy and/or surgery.	01-14-2010
20100021424	Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours.	01-28-2010
20100029912	Fusion Protein - Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.	02-04-2010
20100247580	Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy - The present invention relates to gene expression profiles; methods for classifying patients; microarrays; and treatment of population of patients selected through use of methods and microarrays as described herein.	09-30-2010
20110070268	Method - Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours.	03-24-2011

Jamila Louahed, Plymouth Meeting, PA US

Patent application number	Description	Published
20090068185	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders - A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.	03-12-2009
20090191191	Methods for the Modulation of IL-13 - The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.	07-30-2009

Jamila Louahed, Brussels BE

Patent application number	Description	Published
20080213881	Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof - The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.	09-04-2008